Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer

BACKGROUND: Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited. This analysis is a retrospective evaluation...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Young Joo, Joo, Kwang Ro, Park, Neung Hwa, Yun, Tae Kwon, Nah, Yang Won, Nam, Chang Woo, Park, Jae Hoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2002
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531686/
https://www.ncbi.nlm.nih.gov/pubmed/12647642
http://dx.doi.org/10.3904/kjim.2002.17.4.259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531686/
https://www.ncbi.nlm.nih.gov/pubmed/12647642
http://dx.doi.org/10.3904/kjim.2002.17.4.259

Ejemplares similares